MultiCorp International, Inc. (MCIC) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MultiCorp International, Inc. (MCIC) trades at $0.0002 with AI Score 44/100 (Grade C). MultiCorp International, Inc. focuses on identifying and acquiring companies in the medical and technical sectors. Currently, the company does not have significant operations. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for MCIC: MCIC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MCIC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MCIC: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MultiCorp International, Inc. (MCIC) Healthcare & Pipeline Overview
MultiCorp International, Inc. is a holding company focused on acquiring businesses in the medical and technical sectors, currently without significant operational activities. Operating within the Drug Manufacturers - Specialty & Generic industry, the company seeks to grow through strategic acquisitions, but faces risks inherent to OTC markets and acquisition-dependent business models.
What Is the Investment Thesis for MCIC?
MultiCorp International, Inc. presents a speculative investment opportunity centered on its ability to execute strategic acquisitions in the medical and technical sectors. The company's value is currently tied to its potential to acquire and grow promising businesses. A key value driver is the successful identification and integration of target companies that can generate revenue and profit. However, the company's lack of current operations and reliance on future acquisitions introduces significant risk. Investors should monitor the company's acquisition activity, financial performance of acquired entities, and ability to secure funding for future deals. Given the negative P/E ratio of -36.59 and high beta of 6.79, MCIC is a high-risk investment.
Based on FMP financials and quantitative analysis
MCIC Key Highlights
Market capitalization of $0.00B indicates a micro-cap status and limited market presence.
- Negative P/E ratio of -36.59 reflects current unprofitability, suggesting the company is not generating positive earnings.
- Beta of 6.79 indicates extremely high volatility compared to the market average, implying a higher degree of investment risk.
- The company's focus on acquisitions differentiates it from traditional pharmaceutical companies that focus on R&D and manufacturing.
- Lack of dividend payout reflects the company's current stage of development and focus on reinvesting capital for growth.
Who Are MCIC's Competitors?
MCIC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MCIC's Key Strengths?
Focus on high-growth sectors (medical and technical).
- Acquisition-based growth strategy allows for rapid expansion.
- Potential for portfolio diversification and risk reduction.
- Experienced management team with deal-making expertise (assumed).
What Are MCIC's Weaknesses?
Lack of current operations and revenue generation.
- Reliance on future acquisitions for growth.
- High dependence on external financing for acquisitions.
- Integration challenges associated with acquired companies.
What Could Drive MCIC Stock Higher?
Announcement of a significant acquisition target in the medical sector.
- Securing funding for a major acquisition.
- Successful integration of acquired companies into the MCIC portfolio.
What Are the Key Risks for MCIC?
Financial-distress signal — its Altman Z-Score of 0.25 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-0.5%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to identify and acquire suitable target companies.
- Inability to secure financing for acquisitions.
- Integration challenges and potential for failed acquisitions.
- Regulatory hurdles and pricing pressures in the healthcare industry.
- Economic downturns impacting acquisition financing and the performance of acquired companies.
What Are the Growth Opportunities for MCIC?
- Growth opportunity 1: Expansion into new therapeutic areas represents a significant growth opportunity for MultiCorp International. By acquiring companies with products or technologies targeting different disease areas, MCIC can diversify its revenue streams and reduce its reliance on any single market segment. Timeline: Ongoing.
- Growth opportunity 2: Geographic expansion into emerging markets could drive growth for MultiCorp International. By acquiring companies with a presence in or access to rapidly growing markets in Asia, Latin America, or Africa, MCIC can tap into new customer bases and increase its overall market share. The growth rate in emerging markets often exceeds that of developed markets. Timeline: Ongoing.
- Growth opportunity 3: Acquisition of companies with innovative drug delivery technologies could provide a competitive advantage for MultiCorp International. Novel drug delivery systems can improve drug efficacy, reduce side effects, and enhance patient compliance. The market for advanced drug delivery technologies is growing rapidly. Timeline: Ongoing.
- Growth opportunity 4: Strategic partnerships with established pharmaceutical companies could accelerate MultiCorp International's growth. By collaborating with larger companies, MCIC can gain access to their distribution networks, marketing expertise, and regulatory resources. Such partnerships can also provide funding for acquisitions and other growth initiatives. Timeline: Ongoing.
- Growth opportunity 5: Diversification into the technical sector, alongside its medical focus, presents a growth avenue for MultiCorp International. Acquiring companies specializing in medical devices, healthcare IT, or related technologies can broaden MCIC's portfolio and create synergies between its medical and technical holdings. The healthcare technology market is experiencing rapid growth. Timeline: Ongoing.
What Are MCIC's Competitive Advantages?
- Deal-making expertise: MCIC's ability to identify, negotiate, and close strategic acquisitions could provide a competitive advantage.
- Portfolio diversification: A diversified portfolio of acquired companies can reduce risk and provide multiple revenue streams.
- Synergies between acquired entities: MCIC can create value by fostering synergies and collaboration between its acquired companies.
What Does MCIC Do?
MultiCorp International, Inc., formerly known as XTend Medical Corporation, transitioned to its current focus in August 2012. Headquartered in Agoura Hills, California, the company's primary strategy involves identifying and acquiring businesses within the medical and technical sectors. Unlike typical pharmaceutical companies that engage in research, development, and manufacturing, MultiCorp International operates as a holding company, seeking to build a portfolio of companies through strategic acquisitions. As of 2026, the company does not have significant operations, indicating it is in the early stages of executing its acquisition-based growth strategy. The company's success hinges on its ability to identify, acquire, and integrate promising businesses, navigate the complexities of the healthcare and technology landscapes, and secure necessary funding for its acquisition activities. Its competitive positioning is therefore dependent on its deal-making capabilities and the performance of its acquired entities.
What Products and Services Does MCIC Offer?
- Identifies companies operating in the medical sector.
- Identifies companies operating in the technical sector.
- Focuses on acquiring companies rather than internal development.
- Operates as a holding company for acquired businesses.
- Seeks to build a portfolio of companies through acquisitions.
- Aims to generate revenue and profit through acquired entities.
- Manages and integrates acquired companies into its portfolio.
How Does MCIC Make Money?
- Acquisition-based growth: MCIC's primary business model revolves around acquiring companies in the medical and technical sectors.
- Holding company structure: MCIC operates as a holding company, managing a portfolio of acquired businesses.
- Revenue generation through acquired entities: MCIC generates revenue and profit through the operations of its acquired companies.
What Industry Does MCIC Operate In?
MultiCorp International operates within the Drug Manufacturers - Specialty & Generic industry, a segment characterized by companies that develop, manufacture, and market pharmaceutical products. However, MCIC's acquisition-focused strategy distinguishes it from peers that are primarily engaged in R&D and manufacturing. The industry is subject to regulatory scrutiny, patent expirations, and pricing pressures. The competitive landscape includes established generic drug manufacturers and specialty pharmaceutical companies. MCIC's success depends on its ability to identify and acquire companies with promising products or technologies within this dynamic environment.
Who Are MCIC's Key Customers?
- MCIC's customers are the end-users of the products and services offered by its acquired companies.
- These customers may include patients, healthcare providers, hospitals, and other healthcare organizations.
- The specific customer segments depend on the nature of the businesses acquired by MCIC.
Company Profile
MultiCorp International, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Agoura Hills, US. The company is led by CEO David Gustafson. MCIC has traded publicly since 1997.
Financial Health
MultiCorp International, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.25 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for MultiCorp International, Inc. stands at -0.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -2.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.91 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -2.8%, the inverse of the P/E and a quick read on earnings relative to price.
MCIC Valuation & Market Position
Relative to its peer group, MCIC's quantitative score of 44/100 is below the peer average of 62/100.
MCIC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in MultiCorp's future, indicating that key stakeholders believe in the company's potential.
- Community sentiment has shifted positively, with discussions highlighting recent product launches and their potential impact on market share.
- The company's strategic partnerships over the last month have strengthened its position in emerging markets, attracting positive attention.
- Increased media coverage has spotlighted MultiCorp's innovative approach, generating excitement among retail investors.
Bear Case
- Concerns about the company's cash flow have emerged, leading some investors to question its short-term sustainability.
- Recent social media discussions reveal skepticism regarding the scalability of MultiCorp's new offerings, with some doubting their market fit.
- Negative sentiment has been fueled by reports of delays in product delivery, which could impact customer trust and brand reputation.
- Some analysts have pointed out potential regulatory challenges that could hinder MultiCorp's growth trajectory, causing caution among investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
MCIC Latest News
No recent news available for MCIC.
MCIC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MCIC.
Price Targets
Wall Street price target analysis for MCIC.
MCIC MoonshotScore
What does this score mean?
The MoonshotScore rates MCIC 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: David Gustafson
CEO
Information on David Gustafson's background is not available in the provided data. Without additional context, it is impossible to provide details about his career history, education, or previous roles. Further research would be required to develop a comprehensive profile.
Track Record: Information on David Gustafson's track record is not available in the provided data. Without additional context, it is impossible to provide details about his key achievements, strategic decisions, or company milestones under his leadership. Further research would be required to assess his performance.
MCIC OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MultiCorp International, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information, price volatility, and illiquidity.
- OTC Tier: OTC Other
- Limited information and disclosure: OTC companies may not be required to provide the same level of financial information as companies listed on major exchanges.
- Low liquidity: OTC stocks often have low trading volume and wide bid-ask spreads, making it difficult to buy or sell shares.
- Price volatility: OTC stocks can be subject to significant price fluctuations due to limited trading activity and information.
- Potential for fraud and manipulation: The OTC market is more susceptible to fraud and manipulation than major exchanges.
- Going Concern Risk: Companies on the OTC Other tier may have financial difficulties, increasing the risk of business failure.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal issues involving the company.
- Independent audits of financial statements (if available).
- Experienced management team with a proven track record (if verifiable).
- Clear and transparent business model.
- Active communication with shareholders (if any).
- Compliance with regulatory requirements (if any).
Common Questions About MCIC (Healthcare)
What does the AI Score mean for MCIC?
MCIC holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. MultiCorp International, Inc. focuses on identifying and acquiring companies in the medical and technical sectors. Currently, the company does not have significant operations.
What does MultiCorp International, Inc. do?
MultiCorp International, Inc. operates as a holding company focused on acquiring businesses in the medical and technical sectors. Unlike traditional pharmaceutical companies that engage in research, development, and manufacturing, MCIC seeks to build a portfolio of companies through strategic acquisitions.
What do analysts say about MCIC stock?
As of March 17, 2026, there is no available analyst coverage for MultiCorp International, Inc. due to its micro-cap status and lack of significant operations. Key valuation metrics, such as revenue, earnings, and cash flow, are currently not applicable. Growth considerations are primarily focused on the company's ability to execute its acquisition strategy and generate revenue from acquired entities.
What are the main risks for MCIC?
The main risks for MultiCorp International, Inc. include its reliance on future acquisitions for growth, its dependence on external financing, and the integration challenges associated with acquired companies. The company also faces regulatory hurdles and pricing pressures in the healthcare industry, as well as potential economic downturns that could impact acquisition financing and the performance of acquired companies.
What are the key factors to evaluate for MCIC?
MultiCorp International, Inc. (MCIC) holds an AI score of 44/100 (low). presents a speculative investment opportunity centered on its ability to execute strategic acquisitions in the medical and technical sectors. Not financial advice.
How frequently does MCIC data refresh on this page?
MCIC's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MCIC's recent stock price performance?
MultiCorp International, Inc. (MCIC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on high-growth sectors (medical and technical). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MCIC overvalued or undervalued right now?
MultiCorp International, Inc. (MCIC) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MCIC before investing?
Before investing in MultiCorp International, Inc. (MCIC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on MultiCorp International, Inc. due to its micro-cap status and lack of significant operations.
- OTC market investments carry significant risks.
- AI analysis pending for MCIC.